USA-based biotech firm Amgen (Nasdaq: AMGN) and its subsidiary Onyx Pharmaceuticals have announced the interim results of a Phase III head-to-head trial evaluating Kyprolis (carfilzomib) and dexamethasone versus Velcade (bortezomib) and dexamethasone.
The ENDEAVOR trial evaluated Kyprolis and Velcade with low doses of dexamethasone in treating relapsed multiple myeloma, and found that it met its primary endpoint of progression-free survival.
Patients with relapsed multiple myeloma treated with Kyprolis lived twice as long (18.7 months versus 9.4 months) without their disease worsening, demonstrating statistical and clinical superiority over Velcade.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze